Kolarić K, Maricić Z, Roth A, Dujmović I
Cancer. 1980 May 1;45(9):2265-73. doi: 10.1002/1097-0142(19800501)45:9<2265::aid-cncr2820450908>3.0.co;2-7.
In a prospective randomized study, 31 patients with inoperable esophageal cancer were treated with a combination of bleomycin and adriamycin, and with a combination of these cytostatics and radiation. Evaluation of treatment results showed 3 partial remissions and 2 stable-disease cases in the group of 16 patients treated by cytostatic drugs alone; in all other cases, the disease progressed. The response rate achieved in this group was 19%. In the group including 15 patients who were irradiated with a dose of 3600--4000 rad and received simultaneously the same cytostatics with a somewhat lower dose of adriamycin, there were 3 complete remissions, 6 partial remissions, and 4 stable-disease cases, while in 2 cases the disease progressed. The response rate was 60%, which was statistically significant (P less than 0.025) when compared with the results achieved by the group receiving the bleomycin adriamycin combination. The average duration of remissions in the complete-response cases was 11 months, and in the partial-response cases, 5.2 months with combined treatment, and 4.2 months with combination chemotherapy. The toxic side-effects were tolerable for the patients, albeit more intensive with the combined-treatment modality. Four esophagobronchial fistulas (four disease progressions) and one rupture of the aorta were noted during treatment. This study has shown the advantages of chemoradiotherapeutic treatment of inoperable esophageal cancer.
在一项前瞻性随机研究中，31例无法手术的食管癌患者接受了博来霉素和阿霉素联合治疗，以及这些细胞抑制剂与放疗的联合治疗。治疗结果评估显示，仅接受细胞抑制剂治疗的16例患者中，有3例部分缓解，2例病情稳定；在所有其他病例中，病情进展。该组的缓解率为19%。在包括15例接受3600 - 4000拉德剂量放疗并同时接受相同细胞抑制剂且阿霉素剂量略低的患者组中，有3例完全缓解，6例部分缓解，4例病情稳定，而有2例病情进展。缓解率为60%，与接受博来霉素 - 阿霉素联合治疗组的结果相比，具有统计学意义（P小于0.025）。完全缓解病例的平均缓解持续时间为11个月，部分缓解病例在联合治疗时为5.2个月，在联合化疗时为4.2个月。尽管联合治疗方式的毒性副作用更强烈，但患者仍可耐受。治疗期间发现4例食管气管瘘（4例病情进展）和1例主动脉破裂。这项研究显示了对无法手术的食管癌进行放化疗治疗的优势。
